Advice

Marketing Authorisation Withdrawn

On 2 March, 2018, the European Medicines Agency (EMA) published a statement regarding daclizumab (Zinbryta) in adult patients for the treatment of relapsing forms of multiple sclerosis.

Subsequently, the manufacturer, Biogen have voluntarily withdrawn the marketing authorization.

Medicine details

Medicine name:
daclizumab (Zinbryta)
SMC ID:
1216/17
Indication:
In adult patients for the treatment of relapsing forms of multiple sclerosis.
Pharmaceutical company
Biogen Idec Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full submission
Status
Withdrawn
Date advice published:
10 April 2017